Automation Leader CYTENA offers automated single-cell isolation and fully automated cell line development platforms (C.STATION) with high viability and clonality assurance, presenting a strong upsell opportunity to biopharma and contract development manufacturers looking to scale monoclonal antibody production and gene therapy workflows.

Cross‑Sample Integrity Emphasize purity benefits from disposable cartridges that prevent cross-contamination, which is a compelling differentiator for customers handling multiple samples or regulated environments, including pharmaceutical giants and academic labs pursuing cleanroom-compatible workflows.

Early Adoption Recent launches such as C.WASH PLUS and the historical introduction of C.STATION indicate a continuous product upgrade cycle and commitment to workflow automation, making CYTENA a favorable partner for customers aiming to modernize biotherapeutic development pipelines.

Broad Applicability Instruments support diverse cell types including bacteria and are used across academic research and large pharma for monoclonal line development, single-cell analysis, and biotherapeutic workflows, enabling cross‑vertical sales conversations with biotech incubators, CROs, and pharma R&D groups.

Strategic Partnerships Existing collaborations with CDMOs like ExcellGene and a track record with top ten pharma customers open doors for co‑development, integrated automation workflows, and potential joint selling opportunities for end‑to‑end cell line development and biotherapeutic production.